Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 15.494 Notifications successully processed since Inception
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US2521311074
State: 14.11.2024 | 12AM
Do you already know our new terminal view? Click here.
FIGI: BBG000QTF8K1
DXCM
DexCom, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Medical Devices
NAME
DexCom, Inc.
ISIN
US2521311074
TICKER
DXCM
MIC
XNAS
REUTERS
DXCM.OQ
BLOOMBERG
DXCM US
Thu, 24.10.2024       DexCom
US2521311074

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis. U.S. revenue declined 2% and international revenue grew 12% on a reported...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Mon, 21.10.2024       DexCom
US2521311074

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faru...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Fri, 18.10.2024       DexCom
US2521311074

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an “international company that develops, manufactures, and distributes continuous glucose monitoring syst...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Thu, 17.10.2024       DexCom
US2521311074

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”). If you are a shareho...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.10.2024       DexCom
US2521311074

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”) The lead p...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Wed, 09.10.2024       DexCom
US2521311074

Labaton Keller Sucharow LLP (“Labaton”) announces that, on October 8, 2024, it filed a securities class action lawsuit (the “Complaint”) on behalf of its clients Oakland County Employees’ Retirement System and Oakland County Voluntary Employees’ Beneficiary Association (the “Oakland County Funds”) against DexCom, Inc. (“DexCom” or the “Company”) (...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Tue, 24.09.2024       DexCom
US2521311074

Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in DexCom and have suffered losses, you may CLICK HERE to contact us. Yo...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Mon, 23.09.2024       DexCom
US2521311074

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in partnership with the nonprofit Beyond Type 2, are teaming up with author, producer and actress Retta to establish National Glucose Awareness Week from Sept. 23-29, 2024. National Glucose Awareness Week will help close the glucose k...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Wed, 18.09.2024       DexCom
US2521311074

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company’s groundbreaking NIL (name, image, likeness) program exclusively for college athletes with diabetes. This press release features multimedia. View the full ...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Wed, 18.09.2024       DexCom
US2521311074

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Dexcom Inc. (“Dexcom” or the “Company”) (NASDAQ: DXCM) securities during the period of January 8, 2024 to July 25, 2024, inclusive (“the Class Period”). ...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Tue, 10.09.2024       DexCom
US2521311074

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better understand the effects of spaceflight o...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Thu, 05.09.2024       DexCom
US2521311074

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violatio...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.09.2024       DexCom
US2521311074

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will spotlight the significant benefits of its innovative CGM technology at an upcoming symposium during the European Association for the Study of Diabetes (EASD) Conference on Monday, 9th September, 1300 – 1430 CEST. The symposi...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Tue, 03.09.2024       DexCom
US2521311074

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired DexCom Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024. DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for d...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Fri, 30.08.2024       DexCom
US2521311074

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Dexcom Inc. (“Dexcom” or the “Company”) (NASDAQ: DXCM) securities during the period of January 8, 2024 to July 25, 2024, inclusive (“the Class Period”). Investor...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Wed, 28.08.2024       DexCom
US2521311074

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violatio...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Wed, 28.08.2024       DexCom
US2521311074

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, and Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4th. The live presentation is scheduled to begin at app...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Mon, 26.08.2024       DexCom
US2521311074

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class P...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Mon, 26.08.2024       DexCom
US2521311074

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”). DexCom investors have until October 21, 2024 to fil...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Mon, 26.08.2024       DexCom
US2521311074

Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-0148...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.